A recent study in the CHEST Journal showed no significant difference in acute respiratory failure outcomes between patients who received nitric oxide versus epoprostenol. Radical! Which agent is preferred at your facility? https://t.co/C7aHJ5l8U3
Inhaled Nitric Oxide vs Epoprostenol During Acute Respiratory Failure: An Observational Target Trial Emulation.
Mentions
Extended reach
Total likes
Video views
Mentions per month
Aug 2022 – Aug 2025Where it's discussed
-
X / Twitter3 posts
-
News3 articles
-
YouTube1 videos
AI synopsis
What people are saying
The discussions reflect a mostly neutral to positive reception, with phrases like 'Radical!' indicating some excitement, while others focus on the practical implications such as hospital preferences. The tone combines curiosity and acknowledgment of the research’s importance, contributing to a nuanced overall assessment.
Most posts interpret the study as confirming that there’s no significant difference between the two treatments, showing general agreement with the findings.
Posts reveal a moderate level of interest, mentioning the implications for clinical practice and hospital preferences, indicating engagement beyond basic acknowledgment.
Discussions reference specific outcomes like extubation success and hospital costs, suggesting thoughtful participation and analysis.
The tone and content imply that the study’s results could influence clinical decisions and hospital policies, indicating a moderate level of impact.
Abstract in brief
- The study compared the effectiveness of inhaled nitric oxide and epoprostenol, two vasodilators used to improve oxygenation in patients with severe acute respiratory failure, finding no significant difference in successful extubation rates, hospital costs, or mortality between the two treatments.
- Researchers used a large US hospital database to analyze practice patterns and outcomes, focusing on hospitals that exclusively used one of the treatments to reduce bias.
- The findings highlight significant variation across hospitals in the choice of inhaled vasodilators, but overall, both therapies showed similar effectiveness in managing severe respiratory failure.]
Top posts
Most liked on X and BlueskyNo differences in likelihood of successful extubation between patients in inhaled nitric oxide-only versus inhaled epoprostenol-only hospitals for acute respiratory failure. No differences in total hospital costs or death #MedEd #MedTwitter #PCCMTwitter https://t.co/DLC66LA0vI
All mentions
Inhaled Nitric Oxide vs Epoprostenol in ARDS: Effectiveness and Costs Comparison
This study compares inhaled nitric oxide and epoprostenol for severe respiratory failure, finding similar success rates and hospital costs, but higher drug-specific costs for nitric oxide, emphasizing consideration of…
A recent study in the CHEST Journal showed no significant difference in acute respiratory failure outcomes between patients who received nitric oxide versus epoprostenol. Radical! Which agent is preferred at your facility? https://t.co/C7aHJ5l8U3
RT @PagingDrAyman: No differences in likelihood of successful extubation between patients in inhaled nitric oxide-only versus inhaled epopr…
No differences in likelihood of successful extubation between patients in inhaled nitric oxide-only versus inhaled epoprostenol-only hospitals for acute respiratory failure. No differences in total hospital costs or death #MedEd #MedTwitter #PCCMTwitter https://t.co/DLC66LA0vI